Therapeutic strategies in male breast cancer: Clinical implications of chromosome 17 gene alterations and molecular subtypes
Open Access
- 30 September 2013
- journal article
- research article
- Published by Elsevier BV in The Breast
- Vol. 22 (6), 1066-1071
- https://doi.org/10.1016/j.breast.2013.08.008
Abstract
No abstract availableKeywords
Funding Information
- German Cancer Foundation
This publication has 45 references indexed in Scilit:
- Molecular subtyping of male breast cancer by immunohistochemistryLaboratory Investigation, 2012
- Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarkerBreast Cancer Research, 2012
- Men With Breast Cancer Have Same Disease-Specific and Event-Free Survival as WomenAnnals of Surgical Oncology, 2009
- Prognostic Factors in Node-Negative Male Breast CancerClinical Breast Cancer, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- Breast carcinoma in menCancer, 2004
- Is Male Breast Cancer Similar or Different than Female Breast Cancer?Breast Cancer Research and Treatment, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001